首页> 美国卫生研究院文献>The Journal of Biological Chemistry >Linker Length Matters Fynomer-Fc Fusion with an Optimized Linker Displaying Picomolar IL-17A Inhibition Potency
【2h】

Linker Length Matters Fynomer-Fc Fusion with an Optimized Linker Displaying Picomolar IL-17A Inhibition Potency

机译:接头长度很重要Fynomer-Fc融合蛋白具有优化的接头可显示皮摩尔IL-17A抑制潜能

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fynomers are small binding proteins derived from the human Fyn SH3 domain. Using phage display technology, Fynomers were generated inhibiting the activity of the proinflammatory cytokine interleukin-17A (IL-17A). One specific Fynomer called 2C1 inhibited human IL-17A in vitro with an IC50 value of 2.2 nm. Interestingly, when 2C1 was genetically fused to the Fc part of a human antibody via four different amino acid linkers to yield bivalent IL-17A binding proteins (each linker differed in length), the 2C1-Fc fusion protein with the longest linker displayed the most potent inhibitory activity. It blocked homodimeric IL-17A with an IC50 value of 21 pm, which corresponds to a hundredfold improved IC50 value as compared to the value obtained with monovalent Fynomer 2C1. In contrast, the 2C1-Fc fusion with the shortest linker showed only an ∼8-fold improved IC50 value of 260 pm. Furthermore, in a mouse model of acute inflammation, we have shown that the most potent 2C1-Fc fusion protein is able to efficiently inhibit IL-17A in vivo. With their suitable biophysical properties, Fynomer-Fc fusion proteins represent new drug candidates for the treatment of IL-17A mediated inflammatory conditions such as psoriasis, psoriatic arthritis, or rheumatoid arthritis.
机译:Fynomer是衍生自人Fyn SH3域的小结合蛋白。使用噬菌体展示技术,可以产生抑制促炎细胞因子白介素17A(IL-17A)活性的Fynomers。一种称为2C1的特定Fynomer在体外抑制人IL-17A,IC50值为2.2 nm。有趣的是,当2C1通过四个不同的氨基酸接头与人抗体的Fc部分遗传融合以产生二价IL-17A结合蛋白(每个接头的长度不同)时,具有最长接头的2C1-Fc融合蛋白显示出最多的强大的抑制活性。它以21 pm的IC50值阻断了同型二聚体IL-17A,与单价Fynomer 2C1获得的IC50值相比,其IC50值提高了一百倍。相比之下,具有最短接头的2C1-Fc融合物的IC50值仅为260 pm,仅提高了约8倍。此外,在急性炎症的小鼠模型中,我们显示出最有效的2C1-Fc融合蛋白能够在体内有效抑制IL-17A。具有合适的生物物理特性,Fynomer-Fc融合蛋白代表了用于治疗IL-17A介导的炎性疾病(如牛皮癣,银屑病关节炎或类风湿性关节炎)的新药物候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号